Search

Displaying results 2651 - 2660 of 4539 in total
  1. Drug

    Talimogene laherparepvec

    go.drugbank.com/drugs/DB13896
    ApprovedInvestigational

    It was approved by the FDA in 2015 under the market name Imlygic. In general, talimogene laherparepvec has been modified so that it can infect and multiply inside melanoma cells [L2221].

  2. Drug

    Ichthammol

    go.drugbank.com/drugs/DB11341
    Approved

    It is an ammonium salt of dark sulfonated shale oil (bituminous schists) produced via distillation of the oil followed by sulfonation and neutralization.

  3. Drug

    Iloperidone

    go.drugbank.com/drugs/DB04946
    ApprovedInvestigational

    Iloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009.

  4. Drug

    Calcium glucoheptonate

    go.drugbank.com/drugs/DB00326
    ApprovedInvestigational

    Calcium supplements such as calcium gluceptate are taken by individuals who are unable to get enough calcium in their regular diet or who have a need for more calcium.

  5. Drug

    Larazotide

    go.drugbank.com/drugs/DB05645
    Investigational

    An octapeptide inhibitor of paracellular permeability whose structure is derived from a protein (zonula occludens toxin) secreted by Vibrio cholerae for treatment of Coeliac disease.

  6. Drug

    Lesopitron

    go.drugbank.com/drugs/DB04970
    Experimental

    Lesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.

  7. Drug

    MDX-1303

    go.drugbank.com/drugs/DB05945
    Investigational

    MDX-1303 is a fully human antibody against the inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium, and targets a protein component of these lethal

  8. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.

  9. Drug

    Calaspargase pegol

    go.drugbank.com/drugs/DB14730
    ApprovedInvestigational

    Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) [L4890].

  10. Drug

    Manganese gluconate

    go.drugbank.com/drugs/DB11141
    Approved

    It is typically obtained by reacting manganese carbonate with gluconic acid in aqueous medium and then crystallizing the product to form a slightly pink powder.

    Mixtures: Cal-mag Plus K, Mn and Zn Caplets